Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer
Abstract Liquid biopsy has become a useful alternative in metastatic colorectal cancer (mCRC) patients when tissue biopsy of metastatic sites is not feasible. In this study we aimed to investigate the clinical utility of circulating exosomes DNA in the management of mCRC patients. Exosomes level and...
Guardado en:
Autores principales: | Donatella Lucchetti, Ina Valeria Zurlo, Filomena Colella, Claudio Ricciardi-Tenore, Mariantonietta Di Salvatore, Giampaolo Tortora, Ruggero De Maria, Felice Giuliante, Alessandra Cassano, Michele Basso, Antonio Crucitti, Ilaria Laurenzana, Giulia Artemi, Alessandro Sgambato |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/76b8a6a6c9ab48f3a5d635c255f279da |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Nicolas Bery, et al.
Publicado: (2020) -
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Jieqiong Wang, et al.
Publicado: (2016) -
Oncogenic KRAS: Signaling and Drug Resistance
por: Hyeon Jin Kim, et al.
Publicado: (2021) -
Two Novel Precursors of the HIV-1 Protease Inhibitor Darunavir Target the UPR/Proteasome System in Human Hepatocellular Carcinoma Cell Line HepG2
por: Roberta Rinaldi, et al.
Publicado: (2021) -
Immune modulatory effects of oncogenic KRAS in cancer
por: Shaima’a Hamarsheh, et al.
Publicado: (2020)